BACKGROUND: The effect on Paco2 of high concentration oxygen therapy when administered to patients with severe exacerbations of asthma is uncertain. METHODS:106 patients with severe exacerbations of asthma presenting to the Emergency Department were randomised to high concentration oxygen (8 l/min via medium concentration mask) or titrated oxygen (to achieve oxygen saturations between 93% and 95%) for 60 min. Patients with chronic obstructive pulmonary disease or disorders associated with hypercapnic respiratory failure were excluded. The transcutaneous partial pressure of carbon dioxide (Ptco2) was measured at 0, 20, 40 and 60 min. The primary outcome variable was the proportion of patients with a rise in Ptco2 ≥4 mm Hg at 60 min. RESULTS: The proportion of patients with a rise in Ptco2 ≥4 mm Hg at 60 min was significantly higher in the high concentration oxygen group, 22/50 (44%) vs. 10/53 (19%), RR 2.3 (95% CI 1.2 to 4.4, p<0.006). The high concentration group had a higher proportion of patients with a rise in Ptco2 ≥8 mm Hg, 11/50 (22%) vs. 3/53 (6%), RR 3.9 (95% CI 1.2 to 13.1, p=0.016). All 10 patients with a final Ptco2 ≥45 mm Hg received high concentration oxygen therapy, and in five there was an increase in Ptco2 ≥10 mm Hg. CONCLUSION:High concentration oxygen therapy causes a clinically significant increase in Ptco2 in patients presenting with severe exacerbations of asthma. A titrated oxygen regime is recommended in the treatment of severe asthma, in which oxygen is administered only to patients with hypoxaemia, in a dose that relieves hypoxaemia without causing hyperoxaemia. Clinical trial number ACTRN12607000131459.
RCT Entities:
BACKGROUND: The effect on Paco2 of high concentration oxygen therapy when administered to patients with severe exacerbations of asthma is uncertain. METHODS: 106 patients with severe exacerbations of asthma presenting to the Emergency Department were randomised to high concentration oxygen (8 l/min via medium concentration mask) or titrated oxygen (to achieve oxygen saturations between 93% and 95%) for 60 min. Patients with chronic obstructive pulmonary disease or disorders associated with hypercapnic respiratory failure were excluded. The transcutaneous partial pressure of carbon dioxide (Ptco2) was measured at 0, 20, 40 and 60 min. The primary outcome variable was the proportion of patients with a rise in Ptco2 ≥4 mm Hg at 60 min. RESULTS: The proportion of patients with a rise in Ptco2 ≥4 mm Hg at 60 min was significantly higher in the high concentration oxygen group, 22/50 (44%) vs. 10/53 (19%), RR 2.3 (95% CI 1.2 to 4.4, p<0.006). The high concentration group had a higher proportion of patients with a rise in Ptco2 ≥8 mm Hg, 11/50 (22%) vs. 3/53 (6%), RR 3.9 (95% CI 1.2 to 13.1, p=0.016). All 10 patients with a final Ptco2 ≥45 mm Hg received high concentration oxygen therapy, and in five there was an increase in Ptco2 ≥10 mm Hg. CONCLUSION: High concentration oxygen therapy causes a clinically significant increase in Ptco2 in patients presenting with severe exacerbations of asthma. A titrated oxygen regime is recommended in the treatment of severe asthma, in which oxygen is administered only to patients with hypoxaemia, in a dose that relieves hypoxaemia without causing hyperoxaemia. Clinical trial number ACTRN12607000131459.
Authors: Marija Barbateskovic; Olav L Schjørring; Sara Russo Krauss; Janus C Jakobsen; Christian S Meyhoff; Rikke M Dahl; Bodil S Rasmussen; Anders Perner; Jørn Wetterslev Journal: Cochrane Database Syst Rev Date: 2019-11-27
Authors: Helen K Reddel; Eric D Bateman; Allan Becker; Louis-Philippe Boulet; Alvaro A Cruz; Jeffrey M Drazen; Tari Haahtela; Suzanne S Hurd; Hiromasa Inoue; Johan C de Jongste; Robert F Lemanske; Mark L Levy; Paul M O'Byrne; Pierluigi Paggiaro; Soren E Pedersen; Emilio Pizzichini; Manuel Soto-Quiroz; Stanley J Szefler; Gary W K Wong; J Mark FitzGerald Journal: Eur Respir J Date: 2015-07-23 Impact factor: 16.671
Authors: Hendrik J F Helmerhorst; Marcus J Schultz; Peter H J van der Voort; Evert de Jonge; David J van Westerloo Journal: Crit Care Date: 2015-08-17 Impact factor: 9.097
Authors: Kathryn Maitland; Sarah Kiguli; Robert O Opoka; Peter Olupot-Olupot; Charles Engoru; Patricia Njuguna; Victor Bandika; Ayub Mpoya; Andrew Bush; Thomas N Williams; Richard Grieve; Zia Sadique; John Fraser; David Harrison; Kathy Rowan Journal: Wellcome Open Res Date: 2018-01-09
Authors: George Bardsley; Janine Pilcher; Steven McKinstry; Philippa Shirtcliffe; James Berry; James Fingleton; Mark Weatherall; Richard Beasley Journal: BMC Pulm Med Date: 2018-10-03 Impact factor: 3.317